Search Results Search Sort by RelevanceMost Recent Medicine and Society Dec 2021 Why Disability Must Be Included in Medical School Diversification Efforts Nicole D. Agaronnik, Shahin A. Saberi, Michael Ashley Stein, JD, PhD, and Dorothy W. Tolchin, MD, EdM Ableism in admissions processes and expectations set by technical standards can undermine equity in medical school admissions. AMA J Ethics. 2021;23(12):E981-986. doi: 10.1001/amajethics.2021.981. Case and Commentary Sep 2021 How Should Clinicians and Organizations Assess Risks and Benefits of First-in-Human Implantation of Investigational Devices? Beatrice L. Brown, MBE and Aaron S. Kesselheim, MD, JD, MPH Heightened caution, improved physician and patient communication, and equitable access are key priorities. AMA J Ethics. 2021;23(9):E673-678. doi: 10.1001/amajethics.2021.673. Medical Education Sep 2021 What Should the Public Know About Implantable Material and Device Innovation in the US? Donna-Bea Tillman, PhD, MPA Device innovation has potential to improve patient outcomes over time, yet prospective benefits must be considered in light of risks. AMA J Ethics. 2021;23(9):E697-701. doi: 10.1001/amajethics.2021.697. Policy Forum Nov 2019 Why Quality-of-Life Data Collection and Use Should Be Standardized When Evaluating Candidates for Hand Transplantation Martin Kumnig, PhD, MSc, Emma K. Massey, PhD, and Lisa S. Parker, PhD Improving candidate evaluation and informed consent is key to motivating authenticity, not just voluntariness. AMA J Ethics. 2019;21(11):E974-979. doi: 10.1001/amajethics.2019.974. Policy Forum Feb 2019 What Are Important Ethical Implications of Using Facial Recognition Technology in Health Care? Nicole Martinez-Martin, JD, PhD Applications can identify and monitor patients. They can also diagnose genetic, medical, and behavioral conditions. AMA J Ethics. 2019;21(2):E180-187. doi: 10.1001/amajethics.2019.180. Policy Forum Mar 2016 Medical Malpractice Reform: Historical Approaches, Alternative Models, and Communication and Resolution Programs Joseph S. Kass, MD, JD and Rachel V. Rose, JD, MBA Alternatives to suing could help open communication between injured patients and clinicians. AMA J Ethics. 2016;18(3):299-310. doi: 10.1001/journalofethics.2016.18.3.pfor6-1603. Policy Forum Nov 2022 Informed Consent as a Means of Acknowledging and Avoiding Financial Toxicity as Iatrogenic Harm Kevin Schulman, MD and Barak Richman, PhD, JD Negative health consequences from costly care are referred to as financial toxicity and should be included in informed consent discussions. AMA J Ethics. 2022;24(11):E1063-1068. doi: 10.1001/amajethics.2022.1063. Policy Forum Nov 2022 Necessity for and Limitations of Price Transparency in American Health Care Harold A. Pollack, PhD, MPP More transparent pricing would allow patients and families to make better decisions, but there are limitations to how reliably it promotes efficiency and market discipline. AMA J Ethics. 2022;24(11):E1069-1074. doi: 10.1001/amajethics.2022.1069. Policy Forum Sep 2005 Presumed vs Expressed Consent in the US and Internationally Sheldon Zink, PhD, Rachel Zeehandelaar, and Stacey Wertlieb, MBe Virtual Mentor. 2005;7(9):610-614. doi: 10.1001/virtualmentor.2005.7.9.pfor2-0509. Case and Commentary Aug 2023 Should Organizational Investment in Robotic Surgical Technology Ever Influence Surgeons’ Decisions About Surgical Approach to Patients’ Surgical Care? Ryan D. Rosen, DO and David A. Edelman, MD, MSHPEd Costs partly determine organizational robotics, but questions remain about whether and to what extent they should influence care decisions. AMA J Ethics. 2023;25(8):E575-582. doi: 10.1001/amajethics.2023.575. Pagination Current page 1 Page 2 Next page Next › Last page Last »
Medicine and Society Dec 2021 Why Disability Must Be Included in Medical School Diversification Efforts Nicole D. Agaronnik, Shahin A. Saberi, Michael Ashley Stein, JD, PhD, and Dorothy W. Tolchin, MD, EdM Ableism in admissions processes and expectations set by technical standards can undermine equity in medical school admissions. AMA J Ethics. 2021;23(12):E981-986. doi: 10.1001/amajethics.2021.981.
Case and Commentary Sep 2021 How Should Clinicians and Organizations Assess Risks and Benefits of First-in-Human Implantation of Investigational Devices? Beatrice L. Brown, MBE and Aaron S. Kesselheim, MD, JD, MPH Heightened caution, improved physician and patient communication, and equitable access are key priorities. AMA J Ethics. 2021;23(9):E673-678. doi: 10.1001/amajethics.2021.673.
Medical Education Sep 2021 What Should the Public Know About Implantable Material and Device Innovation in the US? Donna-Bea Tillman, PhD, MPA Device innovation has potential to improve patient outcomes over time, yet prospective benefits must be considered in light of risks. AMA J Ethics. 2021;23(9):E697-701. doi: 10.1001/amajethics.2021.697.
Policy Forum Nov 2019 Why Quality-of-Life Data Collection and Use Should Be Standardized When Evaluating Candidates for Hand Transplantation Martin Kumnig, PhD, MSc, Emma K. Massey, PhD, and Lisa S. Parker, PhD Improving candidate evaluation and informed consent is key to motivating authenticity, not just voluntariness. AMA J Ethics. 2019;21(11):E974-979. doi: 10.1001/amajethics.2019.974.
Policy Forum Feb 2019 What Are Important Ethical Implications of Using Facial Recognition Technology in Health Care? Nicole Martinez-Martin, JD, PhD Applications can identify and monitor patients. They can also diagnose genetic, medical, and behavioral conditions. AMA J Ethics. 2019;21(2):E180-187. doi: 10.1001/amajethics.2019.180.
Policy Forum Mar 2016 Medical Malpractice Reform: Historical Approaches, Alternative Models, and Communication and Resolution Programs Joseph S. Kass, MD, JD and Rachel V. Rose, JD, MBA Alternatives to suing could help open communication between injured patients and clinicians. AMA J Ethics. 2016;18(3):299-310. doi: 10.1001/journalofethics.2016.18.3.pfor6-1603.
Policy Forum Nov 2022 Informed Consent as a Means of Acknowledging and Avoiding Financial Toxicity as Iatrogenic Harm Kevin Schulman, MD and Barak Richman, PhD, JD Negative health consequences from costly care are referred to as financial toxicity and should be included in informed consent discussions. AMA J Ethics. 2022;24(11):E1063-1068. doi: 10.1001/amajethics.2022.1063.
Policy Forum Nov 2022 Necessity for and Limitations of Price Transparency in American Health Care Harold A. Pollack, PhD, MPP More transparent pricing would allow patients and families to make better decisions, but there are limitations to how reliably it promotes efficiency and market discipline. AMA J Ethics. 2022;24(11):E1069-1074. doi: 10.1001/amajethics.2022.1069.
Policy Forum Sep 2005 Presumed vs Expressed Consent in the US and Internationally Sheldon Zink, PhD, Rachel Zeehandelaar, and Stacey Wertlieb, MBe Virtual Mentor. 2005;7(9):610-614. doi: 10.1001/virtualmentor.2005.7.9.pfor2-0509.
Case and Commentary Aug 2023 Should Organizational Investment in Robotic Surgical Technology Ever Influence Surgeons’ Decisions About Surgical Approach to Patients’ Surgical Care? Ryan D. Rosen, DO and David A. Edelman, MD, MSHPEd Costs partly determine organizational robotics, but questions remain about whether and to what extent they should influence care decisions. AMA J Ethics. 2023;25(8):E575-582. doi: 10.1001/amajethics.2023.575.